EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 355 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy MOST POPULAR PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous... December 17, 2025 Addressing Cancer Pain with Complementary Methods (Part 1) April 7, 2023 Husband Turns Wife’s Inspiring Poem for Her Daughters into a Book... February 25, 2020 Cómo compartir los resultados de las pruebas genéticas con la familia March 22, 2022 Load more HOT NEWS Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... Mom Walks In To Comfort Scared Son After Surgery And Sees... BRAF/MEK Inhibition May Be a Viable Treatment Strategy Across the Majority... Reunión anual de la American Society of Clinical Oncology de 2023:...
